Fig. 4From: Dose selection for glycopyrrolate/eFlow® phase III clinical studies: results from GOLDEN (Glycopyrrolate for Obstructive Lung Disease via Electronic Nebulizer) phase II dose-finding studiesPlacebo-adjusted change from baseline in FEV1 AUC0-12 on Day 7 (a: GOLDEN 2; b: GOLDEN 6; c: pooled population). AUC, area under the curve. BID, twice daily. CI, confidence interval. FEV1, forced expiratory volume in 1 second. LS, least squaresBack to article page